Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
Status:
Enrolling by invitation
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Study to evaluate pharmacokinetics, pharmacodynamics and safety of SHR4640 in patients with
mild, moderate hepatic impairment and normal liver function in phase I clinical study.